Efficacy and safety of elinzanetant in vasomotor symptoms associated with menopause: A meta-analysis of randomized controlled trials

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversity of Western Sao Paulo-
Autor(es): dc.contributorUniversity of Miami-
Autor(es): dc.contributorUniversidade Federal de Minas Gerais (UFMG)-
Autor(es): dc.contributorUniversidade Estadual Paulista (UNESP)-
Autor(es): dc.contributorUniversity of Pernambuco-
Autor(es): dc.contributorFederal University of Paraíba-
Autor(es): dc.creatorSobral, Milene Vitória Sampaio-
Autor(es): dc.creatorRocha, Paula-
Autor(es): dc.creatorRodrigues, Livia Kneipp-
Autor(es): dc.creatorBarbosa, Abner Mácola Pacheco-
Autor(es): dc.creatorda Rocha, Naila Camila-
Autor(es): dc.creatorPeres, Clara de Andrade Pontual-
Autor(es): dc.creatorFurtado, Claudio Lucca Lima-
Autor(es): dc.creatorda Silva, Danieli Pereira-
Autor(es): dc.creatorde Moraes, Marina Ayabe Gomes-
Autor(es): dc.creatorAlvarez-Galiana, Veronica-
Data de aceite: dc.date.accessioned2025-08-21T17:18:12Z-
Data de disponibilização: dc.date.available2025-08-21T17:18:12Z-
Data de envio: dc.date.issued2025-04-29-
Data de envio: dc.date.issued2025-04-01-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.1016/j.ejogrb.2025.01.050-
Fonte completa do material: dc.identifierhttps://hdl.handle.net/11449/305839-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/305839-
Descrição: dc.descriptionObjective: To evaluate the efficacy and safety of elinzanetant compared to placebo in patients experiencing vasomotor symptoms (VMS) associated with menopause. Methods: A systematic search of PubMed, Embase, and Cochrane databases identified randomized clinical trials (RCTs) comparing elinzanetant and placebo in patients with menopause-related VMS. Statistical analyses pooled mean difference (MD) and risk ratio (RR) with 95% confidence intervals (CI) using R Studio 4.3.2. Pre-specified outcomes included frequency and intensity of VMS, quality of life, and sleep disturbance. Results: This meta-analysis included three randomized clinical trials reporting data on 995 patients, with 551 receiving elinzanetant. The mean age ranged from 54.4 to 55.6 years. Elinzanetant significantly reduced VMS frequency (MD −3.09; 95 % CI −4.18 to −2.01; I2 = 0 %) and intensity (MD −0.32; 95 % CI −0.43 to −0.21; I2 = 39 %). Improvements in quality of life were demonstrated by reduced scores on the Menopause-Specific Quality of Life Questionnaire (MD −0.46; 95 % CI −0.63 to −0.30; I2 = 35 %) and better sleep quality measured by the Patient-Reported Outcomes Measurement Information System Sleep Disturbance – Short Form 8b (MD −4.65; 95 % CI −5.56 to −3.73; I2 = 0 %). The incidence of adverse events was similar between groups (RR 1.11; 95 % CI 0.99 to 1.25; I2 = 35 %). Conclusion: Elinzanetant reduces the frequency and intensity of VMS and enhances quality of life and sleep quality in patients with menopause-related symptoms. Its safety profile is comparable to placebo.-
Descrição: dc.descriptionUniversity of Western Sao Paulo-
Descrição: dc.descriptionUniversity of Miami-
Descrição: dc.descriptionFederal University of Minas Gerais-
Descrição: dc.descriptionSão Paulo State University-
Descrição: dc.descriptionUniversity of Pernambuco-
Descrição: dc.descriptionFederal University of Paraíba-
Descrição: dc.descriptionSão Paulo State University-
Formato: dc.format142-147-
Idioma: dc.languageen-
Relação: dc.relationEuropean Journal of Obstetrics and Gynecology and Reproductive Biology-
???dc.source???: dc.sourceScopus-
Título: dc.titleEfficacy and safety of elinzanetant in vasomotor symptoms associated with menopause: A meta-analysis of randomized controlled trials-
Tipo de arquivo: dc.typevídeo-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.